A Study of LY317615 in Patients With Brain Tumors

Completed · Phase 2

Conditions studied: Malignant Glioma

In brief

1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.

Key facts

Study ID

NCT00190723

Run by

Eli Lilly and Company

People needed

120

Starts

2002-10-01

Expected to finish

2006-12-01

Last updated by the study team

2007-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You must be at least 18 years old
• You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
• You must be able to swallow the LY317615 tablets

You may not qualify if…

• You are a woman who is pregnant or breastfeeding
• In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.